Literature DB >> 16143328

Genetic deficiency of C3 as well as CNS-targeted expression of the complement inhibitor sCrry ameliorates experimental autoimmune uveoretinitis.

Russell W Read1, Alexander J Szalai, Susan D Vogt, Gerald McGwin, Scott R Barnum.   

Abstract

In this report, we describe the effect of complement deficiency and inhibition on experimental autoimmune uveoretinitis (EAU). C57BL/6 mice genetically deficient in C3 (C3-/-) or expressing a soluble complement activation inhibitor (soluble complement receptor related protein Y or sCrry) in a CNS-targeted fashion, (sCrry/GFAP) were induced for EAU via peripheral immunisation with a peptide of amino acids 1-20 of human interphotoreceptor retinoid binding protein in complete Freund's adjuvant with concurrent intraperitoneal pertussis toxin. The incidence and severity of EAU in the mutant mice was compared with that in simultaneously induced C57BL/6 wild type mice. The sCrry protein was detected in retinal extracts from transgenic but not wild type mice by western blot. C3-/- mice had a significant reduction in the incidence of EAU compared with wild type mice (incidence 44 versus 89%, respectively, p=0.0417) and a significant reduction in the severity of EAU (median disease score values 0 versus 1.3, respectively, p=0.0253). Similarly, sCrry mice had a significant reduction in the incidence of EAU compared with wild type mice (incidence 57 versus 100% respectively, p=0.0033) and a significant reduction in the severity of EAU (median disease score values 0.18 versus 1.85, respectively, p=0.0054). A genetic deficiency of C3 and production of a soluble complement inhibitor targeted to the CNS and eye are protective against EAU.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16143328     DOI: 10.1016/j.exer.2005.07.011

Source DB:  PubMed          Journal:  Exp Eye Res        ISSN: 0014-4835            Impact factor:   3.467


  29 in total

Review 1.  Dynamic control of the complement system by modulated expression of regulatory proteins.

Authors:  Joshua M Thurman; Brandon Renner
Journal:  Lab Invest       Date:  2010-10-04       Impact factor: 5.662

Review 2.  Doyne lecture 2016: intraocular health and the many faces of inflammation.

Authors:  A D Dick
Journal:  Eye (Lond)       Date:  2016-09-16       Impact factor: 3.775

Review 3.  Autoimmune uveitis: clinical, pathogenetic, and therapeutic features.

Authors:  Marcella Prete; Rosanna Dammacco; Maria Celeste Fatone; Vito Racanelli
Journal:  Clin Exp Med       Date:  2015-03-28       Impact factor: 3.984

4.  Complement anaphylatoxin receptors C3aR and C5aR are required in the pathogenesis of experimental autoimmune uveitis.

Authors:  Lingjun Zhang; Brent A Bell; Minzhong Yu; Chi-Chao Chan; Neal S Peachey; John Fung; Xiaoming Zhang; Rachel R Caspi; Feng Lin
Journal:  J Leukoc Biol       Date:  2015-09-22       Impact factor: 4.962

Review 5.  Uveitis: advances in understanding of pathogenesis and treatment.

Authors:  Russell W Read
Journal:  Curr Rheumatol Rep       Date:  2006-08       Impact factor: 4.592

6.  The C5 convertase is not required for activation of the terminal complement pathway in murine experimental cerebral malaria.

Authors:  Theresa N Ramos; Meghan M Darley; Sebastian Weckbach; Philip F Stahel; Stephen Tomlinson; Scott R Barnum
Journal:  J Biol Chem       Date:  2012-06-11       Impact factor: 5.157

Review 7.  The role of complement system in ocular diseases including uveitis and macular degeneration.

Authors:  Purushottam Jha; Puran S Bora; Nalini S Bora
Journal:  Mol Immunol       Date:  2007-09       Impact factor: 4.407

8.  Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis.

Authors:  D A Copland; K Hussain; S Baalasubramanian; T R Hughes; B P Morgan; H Xu; A D Dick; L B Nicholson
Journal:  Clin Exp Immunol       Date:  2009-12-04       Impact factor: 4.330

9.  Association of complement factor H tyrosine 402 histidine genotype with posterior involvement in sarcoid-related uveitis.

Authors:  Ian A Thompson; Baoying Liu; H Nida Sen; Xiadong Jiao; Robert Katamay; Zhiyu Li; Mengjun Hu; Fielding Hejtmancik; Robert B Nussenblatt
Journal:  Am J Ophthalmol       Date:  2013-03-14       Impact factor: 5.258

10.  Role of DAF in protecting against T-cell autoreactivity that leads to experimental autoimmune uveitis.

Authors:  Fengqi An; Qing Li; Zhidan Tu; Hong Bu; Chi-Chao Chan; Rachel R Caspi; Feng Lin
Journal:  Invest Ophthalmol Vis Sci       Date:  2009-05-14       Impact factor: 4.799

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.